Malgorzata Nielacna-Stawicka

Zielona Gora, LB 65046, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018-2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice.

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018-2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice.

Journal: Biomedicines

Published: January 02, 2025

Blood molybdenum level as a marker of cancer risk on BRCA1 carriers.

Blood molybdenum level as a marker of cancer risk on BRCA1 carriers.

Journal: Hereditary cancer in clinical practice

Published: August 01, 2024

Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.

Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.

Journal: Antioxidants (Basel, Switzerland)

Published: June 05, 2024

Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers.

Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers.

Journal: Nutrients

Published: March 26, 2024

Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers.

Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers.

Journal: Nutrients

Published: March 23, 2024

Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers.

Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers.

Journal: Antioxidants (Basel, Switzerland)

Published: March 23, 2024

Epithelial Ovarian Cancer-Varied Treatment Results.

Epithelial Ovarian Cancer-Varied Treatment Results.

Journal: Healthcare (Basel, Switzerland)

Published: May 24, 2023

High-Volume Hospitals' Ovarian Cancer Care-Less Individual Approach or Better Treatment Results?

High-Volume Hospitals' Ovarian Cancer Care-Less Individual Approach or Better Treatment Results?

Journal: Current oncology (Toronto, Ont.)

Published: May 10, 2022

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer.

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer.

Journal: Cancers

Published: January 13, 2021

Showing 1-9 of 9

Last Updated: 09/26/2026